T1	Participants 0 122	Norfloxacin modulates the inflammatory response and directly affects neutrophils in patients with decompensated cirrhosis.
T2	Participants 142 230	Patients with cirrhosis undergoing selective intestinal decontamination with norfloxacin
T3	Participants 367 451	Thirty-one patients with cirrhosis receiving norfloxacin (400 mg/day) were included.
T4	Participants 587 619	Fifty-nine ascitic fluid samples
T5	Participants 2208 2232	patients with cirrhosis.
